Objective. While systemic lupus erythematosus and lupus nephritis (LN) disproportionately affect females, previous studies suggest that males may experience poorer outcomes. We undertook this study to investigate sex differences in health care utilization, end-stage renal disease (ESRD), and mortality among patients with LN receiving Medicaid, public insurance for low-income individuals.
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Objective. While systemic lupus erythematosus and lupus nephritis (LN) disproportionately affect females, previous studies suggest that males may experience poorer outcomes. We undertook this study to investigate sex differences in health care utilization, end-stage renal disease (ESRD), and mortality among patients with LN receiving Medicaid, public insurance for low-income individuals.
Methods. Within the Medicaid Analytic eXtract (MAX) from 29 states (from 2000 to 2010), we used billing claims to identify individuals ages 5-65 years with incident LN (positive predictive value 80%). MAX data were linked to the US Renal Data System to determine ESRD and to Social Security Death Index files to determine death. We estimated adjusted incidence rate ratios (IRRs) by sex for health care utilization using Poisson regression, and we used multivariable proportional hazards models to compare risks of ESRD and death by sex.
Results. Of 2,750 patients with incident LN, 283 (10%) were male. The mean AE SD follow-up period for both sexes was 3.1 AE 2.3 years. The mean AE SD age was 29.6 AE 13.9 years among females and 24.7 AE 14.1 years among males (P < 0.01). Conclusion. In this cohort of patients with incident LN, ESRD and mortality were extremely high overall but were not increased among males compared to females. In this vulnerable population, biologic and health care utilization differences by sex may not significantly affect outcomes.
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease that disproportionately affects females; the prevalence is 6-9 times higher compared to males (1, 2) . Hypotheses for this female predominance include different environmental exposures, sex hormones, cell microchimerisms, and X chromosome dosage (3) . Previous studies suggest that while SLE is rare among males, their disease may be more severe and their damage accrual greater (4) (5) (6) . Males with SLE have been shown to have more cytopenias, hemolytic anemia, cardiovascular disease, and antiphospholipid antibodies, as well as more constitutional symptoms, including fever and weight loss (4, (6) (7) (8) . In addition, a higher proportion of males may present with lupus nephritis (LN) at the time of SLE diagnosis, as well as during the disease course (9, 10) .
The data reported here have been supplied by the United States Renal Data System (USRDS) and by the Centers for Medicare and Medicaid Services under Data Use Agreements. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the United States government.
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Few studies to date have examined differences in end-stage renal disease (ESRD) by sex. One study (n = 93; 31 males) found no sex differences in ESRD or doubling of serum creatinine levels over~40 months of follow-up, but did find that males experienced greater deterioration in renal function (11) . Another retrospective study of 121 patients, 17 of whom were male, found that males had an increased risk of chronic renal insufficiency compared to females (12) (14) . However, another study that used standardized mortality ratios of observed deaths to expected deaths found higher mortality rates among females with SLE (15) .
To our knowledge, there are no incident LN cohort studies in diverse, non-academic center-based US patient populations that have examined sex differences in ESRD or mortality. Similarly, while mortality is more than twice as high among SLE patients with LN than among SLE patients without LN, differences by sex are not well understood (16) . We aimed to study the rates of ESRD and mortality in a diverse, nationwide cohort of patients with incident LN enrolled in Medicaid, the US-based public insurance covering >70 million low-income individuals, to determine whether there were differences by sex. We hypothesized that the rates of both ESRD and mortality would be higher among males. In addition, we aimed to examine health care utilization patterns among patients with LN prior to the development of ESRD. We hypothesized that health care utilization by males would be lower compared to females and, potentially, that delays in seeking care would be related to ESRD, particularly in this vulnerable patient population (17) .
PATIENTS AND METHODS
Cohort identification. We used the Medicaid Analytic eXtract (MAX) with billing claims from all Medicaid beneficiaries from the 29 most populated US states from 2000 to 2010. We identified children and adults ages 5-65 years with ≥3 SLE claims and ≥2 LN claims using a validated International Classification of Diseases, Ninth Revision (ICD-9) code-based algorithm for LN (positive predictive value [PPV] 80%) (18) . We required ≥24 months of continuous enrollment in Medicaid with no LN-related codes (ICD-9 codes for glomerulonephritis, renal failure, or nephrotic syndrome) prior to the first LN code (index date) for inclusion as having incident LN (1).
Outcomes. ESRD. To assess the incidence of ESRD, we merged MAX data with the US Renal Data System (USRDS) data from 2000 to 2010. USRDS is a national data system that integrates demographic and diagnosis data as well as dialysis claims for nearly all patients in the US who receive renal replacement therapy (dialysis or transplantation) (19) . In order for patients to be registered in the Centers for Medicare and Medicaid Services (CMS) ESRD database and to apply for Medicare eligibility, a renal care provider must enroll the patient in USRDS and complete a Medical Evidence Report stating the primary cause of ESRD. Because most individuals in the US with ESRD receive Medicare, Medicaid claims data alone do not allow for a comprehensive assessment of incident ESRD, requiring the linkage of these 2 databases to conduct our analyses. For our primary analysis, we included all cases of ESRD, and for sensitivity analyses, we restricted our outcomes to exclude etiologies other than SLE nephritis and acute or chronic glomerulonephritis.
Mortality. Among patients with ESRD enrolled in USRDS, a Death Notification Form must be completed by renal care providers within 45 days of a death event, and this is enforced by CMS. Therefore, for all patients in our cohort who developed ESRD, mortality was determined from USRDS data. For patients with incident LN enrolled in Medicaid who did not develop ESRD, death was determined using linked Social Security Death Index files. Cause of death was not available for this study for patients with incident LN who died prior to ESRD.
Health care utilization. We assessed health care utilization among all patients with incident LN using emergency department (ED) visits, outpatient visits, and hospitalizations. In secondary analyses, we also examined these factors by sex specifically among those patients who developed ESRD and among those who died, and we restricted our cohort to adults (age ≥18 years).
Covariates. We extracted all covariates during the 12-month period prior to and including the index date (date of first LN-related ICD-9 code). We assessed demographic factors including age, sex, race/ethnicity, geographic region, and zip code-level median household income from American Community Survey data (2006-2010) as a proxy for SES. We also examined medication use, specifically angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), hydroxychloroquine, corticosteroids, and immunosuppressive medications (azathioprine, mycophenolate mofetil, methotrexate, leflunomide, cyclophosphamide, rituximab, tacrolimus, cyclosporine), as well as whether a renal biopsy was performed. We calculated the SLE-specific risk adjustment index, which has been shown to be a better predictor of inpatient mortality among patients with SLE than the Charlson comorbidity index (20, 21) .
Statistical analysis. We compared baseline covariates between males and females using parametric and Proportional hazards models were adjusted for age, race/ethnicity, calendar year of the index date, zip code-level median household income, and the SLE-specific risk adjustment index. We did not include the SLE-specific risk adjustment index in our analyses of the ESRD outcomes as it includes chronic kidney disease, which may lie on the causal pathway.
We also examined use of immunosuppressive agents and corticosteroids and renal biopsy samples following the index date; however, we adjusted for these factors only during the baseline period (183 days prior to and including the index date) and not afterward, as we suspect that they lie on the causal pathway and may mediate and not confound the relationship between sex and adverse outcomes. A mediation analysis was not feasible given our sample size. We tested the proportional hazards assumption (sex multiplied by the natural log of time) and did not find violations in our models. We conducted additional sensitivity analyses to examine whether there were differences in the spacing between the first SLE code in our data set and the first LN-related code by sex. We did not conduct this as a primary analysis given the limitation of including patients with prevalent SLE without knowledge of when their first-ever SLE code occurred. We used Poisson regression to calculate incidence rates (IRs [95% CI]) and incidence rate ratios (IRRs [95% CI]) of health care utilization (ED visits, outpatient visits, and hospitalizations) in the cohort overall and then in secondary analyses among those who developed ESRD and among those who died. IRRs were adjusted for age, race/ethnicity, zip code-level median household income, SLE-specific risk adjustment index, and calendar year of the index date.
All analyses were performed using SAS software, version 9.3 (SAS Institute). We obtained Data Use Agreements for this study from both CMS and USRDS, and data are presented according to federal reporting standards (cell sizes <11 are suppressed). The Partners Human Research Committee at Brigham and Women's Hospital approved this study. All patient information was de-identified prior to our receipt of the data, and therefore informed consent was not possible or required.
RESULTS
We identified 2,467 females and 283 males with incident LN enrolled in Medicaid between 2000 and 2010. The mean AE SD age was 29.6 AE 13.9 years among females and 24.7 AE 14.1 years among males (P < 0.01), and 37% of males were ages 12-17 years compared to 18% of females ( Table 1 ). The mean AE SD follow-up period for both sexes was 3.1 AE 2.3 years. The cohort was racially and ethnically diverse and well-distributed geographically across the US. The zip code-level median household income was similar for both sexes.
Baseline medication use (ACE inhibitors/ARBs, hydroxychloroquine, immunosuppressive agents, and corticosteroids) and numbers of renal biopsies undergone in the 12 months prior to and including the index date were similar for males and females. We also examined the use of ACE inhibitors/ARBs, immunosuppressive medication, and corticosteroids and the number of renal biopsies following the index date. Among patients who were followed up until ESRD, a slightly higher percentage of males received immunosuppressive medications compared to females (64% versus 58%), and a slightly higher percentage of males received ACE inhibitors/ARBs (76% versus 66%). More females than males underwent renal biopsies (38% versus 29%). There was minimal difference in corticosteroid use . In secondary analyses, we examined only those patients who developed ESRD attributed to LN by their attending nephrologist at the time of USRDS enrollment, and among those with diagnoses of LN or any other nephritis. Similarly, we did not find statistically significant differences in our adjusted models by sex for either ESRD or death. We performed 2 additional sensitivity analyses examining both outcomes only among males and females who received immunosuppressive agents during the baseline period and among those who underwent a renal biopsy, and, similarly, we found no differences by sex for either ESRD or death.
In additional sensitivity analyses, we examined time between first SLE code in our data set and first LN-related code. We found that the median time between the first SLE code and the first LN-related code was 62 days (interquartile range [IQR] 0-503 days) for females, with 26% occurring on the same date, compared to 13 days (IQR 0-173 days) for males, with 38% occurring on the same date. Among the females who developed ESRD, 27% had the first SLE code on the same date as the first LN code, compared to 34% of the males. Among the females who died, 30% had the first codes on the same date, compared to 19% of the males. We conducted stratified analyses separating males and females with their first SLE and LN codes on the same date from those with any separation between dates, and then we also stratified by <30 days (versus ≥30 days) between dates and by <60 days (versus ≥60 days) between dates, and we did not find any statistically significant differences in ESRD or death by sex.
Health care utilization by sex. After adjustment for age, sex, race/ethnicity, year, region, median household income, and SLE-specific risk adjustment index, males had lower rates of ED visits ( In additional secondary analyses, we examined utilization specifically among patients with LN who developed ESRD and among those who died in the period between the index date and the outcome of interest (Tables 5 and 6 ). We did not find statistically significant differences in ED visits, outpatient visits, or hospitalizations by sex in either of these groups. However, among patients who developed ESRD and among patients who died, we did observe a trend toward more hospitalizations and fewer ED visits prior to the outcomes among males compared to females.
DISCUSSION
In this high-risk, low-income population of Medicaid beneficiaries with incident LN, we observed extremely high rates of ESRD and mortality overall. In contrast to prior studies that suggested increased risk of adverse outcomes among males with SLE compared to females, rates of ESRD and mortality did not differ by sex in this cohort. Health care utilization, particularly ED visits and outpatient visits, was less frequent for males compared to females overall among patients with incident LN, but was comparable among those patients who developed ESRD or who died.
Overall, compared to other cohorts, the cumulative incidence of ESRD and mortality was substantially higher among this population of Medicaid beneficiaries. In the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, among patients with LN, the 10-year cumulative incidence of ESRD was 10.1% (95% CI 6.6-13.6), compared to the 5-year cumulative incidence in our cohort of 22.3% (95% CI 16.0-29.3) among males and 21.2% (95% CI 19.0-23.5) among females (9) . The SLICC 10-year cumulative incidence of death was 5.9% (95% CI 3.3-8.4) among patients with incident LN, compared to the 5-year cumulative incidence of 9.4% (95% CI 5.4-14.9) among males and 9.8% (95% CI 8.3-11.5) among females in our cohort (9) .
There are several plausible explanations for the increased burden of adverse outcomes observed. The Medicaid population is a low-income population shown * ED = emergency department. † Incidence rates (IRs) per 100 person-years with 95% confidence intervals (95% CIs) starting at the index date of incident lupus nephritis (LN) diagnosis for those individuals who developed end-stage renal disease (ESRD) (n = 394). ‡ Incidence rate ratios (IRRs) adjusted for age, race/ethnicity, year, region, zip code-level median household income, and systemic lupus erythematosus-specific risk adjustment index. * ED = emergency department. † Incidence rates (IRs) per 100 person-years with 95% confidence intervals (95% CIs) starting at the index date of incident lupus nephritis (LN) diagnosis for those individuals who died (n = 190). ‡ Incidence rate ratios (IRRs) adjusted for age and race/ethnicity; additional covariates were not included for model stability due to infrequent outcomes among males.
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to have significant comorbidities and adverse SLE-related outcomes overall (16, 23) . In addition, the quality of care provided to Medicaid beneficiaries with LN has been shown to be suboptimal (24) . Patients with LN-related ESRD have been demonstrated to have poor post-ESRD care as well (25) . Care among Medicaid beneficiaries may be inconsistent given state-to-state differences in continuous enrollment policies and eligibility, and within the Medicaid SLE population, medication adherence has been shown to be poor and acute care utilization to be high (26) . In contrast, the SLICC network consists of academic medical centers, and patients have been shown to receive standard of care treatments and sustained followup over the course of their 12-year follow-up period (9) . The racial/ethnic makeup of the 2 cohorts is also distinctly different, with a significantly higher percentage of black individuals in our cohort and a lower percentage of both white and Hispanic individuals compared to SLICC, which may affect differences in quality of care received as well as outcomes (25) . In addition, the Medicaid population may be enriched with a more severe SLE phenotype, as patients with more aggressive disease may lose their jobs or be unable to work and therefore be more likely to receive public health insurance. Within a cohort of 344 patients with incident SLE in Atlanta, Georgia, the 5-year cumulative incidence of ESRD was 5.2% overall, but only approximately onethird of these patients had early LN at the time of SLE diagnosis (27) . The proportion of ESRD was higher among blacks compared to whites (6.4% versus 2.5%) and significantly higher than in other SLE cohorts in Taiwan and Japan, in which it was~3% (13, 28) . While it is challenging to compare these estimates to LN patients within Medicaid, our finding of ESRD burden was~4 times higher than that in the Georgia cohort, which is more than what might have been expected if only the one-third with LN had had progression of disease. In the Georgia cohort, 79% of patients had ESRD attributed to SLE as reported by USRDS (29) . In our cohort, this proportion was similar.
In the current study, we found comparable rates of ESRD and mortality by sex. Findings from previous studies have varied; some demonstrated increased rates among males, and some, like ours, found no significant differences by sex. Male sex was not associated with ESRD incidence in a study in the Georgia Lupus Registry (27) . In a Taiwanese SLE cohort, there was an increased risk of ESRD among males compared to females (HR 2.2 [95% CI 1.4-3.6]) (13) . In the Hopkins Lupus cohort, there was a doubled odds of renal biopsy, renal insufficiency, and renal failure among males compared to females, with adjustment for age, duration of SLE, ethnicity, and smoking status (4) . In that cohort, male sex was also associated with 2 times greater risk of death (30) . In a US-based inception cohort of~400 patients (17% male), in models adjusted for age, race, insurance status, and area-level socioeconomic indicators, male sex was associated with increased risk of death (14) . However, it is challenging to compare findings across studies, given the variation in patient populations by age, race/ethnicity, and academic care versus non-academic care setting, differences in inclusion of cases of incident versus prevalent SLE or LN, and sparse numbers of males with SLE. While other studies suggest that outcomes may be poorer among males of nonwhite race/ethnicity, we lacked the power to substratify in order to investigate this question in our patient population (4) .
In keeping with previous studies, we found an increased risk of ESRD among black patients with LN overall compared to white patients (27, 31) . This has been attributed to genetic factors (e.g., APOL1 G1 and G2 nephropathy alleles) as well as to health care access and utilization factors (25, 27, 32) . We also found a decreased risk of death among Hispanic patients, which has been previously demonstrated in the Medicaid SLE population (16) . While we did not observe an association between lower zip code-level median household income and ESRD, we did see a relationship with mortality. LN patients living in the poorest areas did have an increased risk of death compared to those in the highest quartile. This finding is with the caveat that nearly all patients in this cohort would be classified as poor, as this is part of the eligibility criteria for enrollment in Medicaid. This association between lower zip code-level median household income and death was attenuated after adjustment for SLE-related comorbidities. The relationship between area-level poverty and accrual of SLE-related damage resulting in adverse outcomes is consistent with findings of a previous study that similarly affirm the detrimental effects of poverty among patients with SLE (33).
We originally hypothesized that an explanation for sex differences in outcomes seen in previous studies may in part be related to differences in health care utilization. In the general population, females have more regular contact with the health care system at younger ages because of pregnancy and increased preventive health measures (e.g., cervical and breast cancer screening) (34) , and therefore, SLE may be detected earlier and at a less severe state. Older male adolescents (ages 16-20 years) have also been shown to have significantly fewer ambulatory care visits both compared to younger males and compared to females of the same age (35) . While we did not find differences in ESRD or mortality in our cohort, we did find that males overall had lower rates of ED visits and outpatient visits compared to females. When we restricted our cohort to adults, we similarly found lower rates of outpatient care utilization among males compared to females. Further studies are needed to delineate whether this difference is related to behavioral differences or SLE disease manifestations and severity, and whether these patterns may contribute to variation in other outcomes beyond ESRD and mortality.
We did find that, compared to females, a greater percentage of males had their first SLE code in our data set on the same date as their first LN-related code (38% versus 26%). However, in stratified analyses, we did not observe differences in either ESRD or mortality by sex when we separately examined those with less versus those with more spacing between code dates. Since this was an incident LN cohort within a prevalent SLE cohort, the interpretation of this sensitivity analysis is limited, and further studies are needed to understand the relationship between duration of SLE at the time of LN onset and sex differences in outcomes.
There were limitations to our study. The use of claims data did not allow us to assess laboratory values or disease activity. Antiphospholipid antibody status is not available using ICD-9 codes; however, we did not observe statistically significant differences in warfarin use by sex. Despite using a conservative definition for LN with high PPV, and despite requiring 2 years without codes to identify incident cases, there may have been some misclassification with prevalent LN. In this cohort, males were younger than females at LN onset and a smaller proportion were black, which may have contributed to our nonsignificant differences in ESRD and mortality in males versus females. However, in models fully adjusted for age, race/ethnicity, SES, and the SLE-specific risk adjustment index, we still did not observe an increased risk of ESRD or death among the males. In addition, race/ethnicity may modify the relationship between sex and adverse outcomes; however, we lacked sufficient power to investigate this question in depth. While our cohort included more males than most studies to date and, unfortunately, adverse outcomes were not uncommon, we still may have been underpowered to detect differences by sex.
In addition, while there were no significant differences in medication use or renal biopsy rates by sex prior to and including the index date, males received more immunosuppressive medications and ACE inhibitors/ ARBs following the index date and underwent fewer renal biopsies. Immunosuppressive therapy and ACE inhibitors/ ARBs are contraindicated in pregnancy and thus are likely to be more limited in use among women of reproductive age. Fewer biopsies among males may relate to lower rates of outpatient care utilization that we observed among males compared to females. However, from the data available, it is not possible to decipher whether the lower percentage of males who underwent renal biopsy was due to patient preference, lower quality of care for males compared to females, or more severe disease on presentation that was treated without biopsy. Given our sample size, and specifically the small number of males receiving immunosuppressive medications who had the outcomes of interest, we were unable to do mediation analyses. We chose not to adjust for these factors in our proportional hazards models as we believed that they were likely to lie on the causal pathway. In addition, overall use of immunosuppressive medications and hydroxychloroquine, the standard of care treatments for patients with LN, was low in this cohort. Previous work in the Medicaid population has affirmed this finding as well (23, 24, 36) .
While we did conduct sensitivity analyses examining adverse outcomes restricted to patients who received immunosuppressive medications and did not find significant differences by sex, we cannot determine whether differences would be apparent if the entire cohort received standard of care regimens. We did demonstrate the ill effects of likely severe, poorly managed disease, as well as the reality that differences by sex may be less pronounced in this setting. Further studies are needed to investigate the role of sex differences in care practices and medication use and the direct impact of these factors on outcomes.
Our study also had a number of strengths. We included a racially and ethnically diverse population of low-income, high-risk individuals with a relatively large number of male SLE patients. Our Medicaid data were linked to USRDS, which captures nearly all ESRD cases in the US. While our findings may not be generalizable to all populations, we focused our study on a large, vulnerable, and diverse patient population, shown in other studies to have an excess burden of adverse outcomes, receiving care at both academic centers and non-academic centers (23, 36, 37) . With 10 years of data and a mean follow-up of
In this large, nationwide study of Medicaid beneficiaries with incident LN, we found extremely high rates of ESRD and mortality but no statistically significant differences by sex in these outcomes. While males had lower rates of ED and ambulatory care visits, we did not observe differences in these severe adverse outcomes. It is plausible that in this especially vulnerable population with overall poor access to high-quality care, biologic differences may be less relevant in shaping adverse outcomes. This contrasts with academic-based cohort studies, in which most patients receive consistent, standard of care therapy. Ongoing studies with extended follow-up and increased numbers of male SLE patients are needed to further investigate the role of genetic and environmental factors, as well as health care quality and use in SLE-related outcomes by sex. The profoundly high rates of ESRD and mortality in this vulnerable population, and the increased risk of death seen among patients living in the poorest areas, provide further evidence that heightened efforts are needed to improve care for these patients.
